Lilly Complements its Drug Discovery Research with Integrated Cellular Screening System from Amersham Biosciences

11-Nov-2003
Amersham, a world leader in medical diagnostics and in Life Sciences, announces that Eli Lilly and Company has purchased an integrated suite of cellular screening technology and licenses to help in the identification of potential therapeutics in its drug discovery program. In addition to the purchase of an IN Cell Analyzer 3000 high-throughput sub-cellular imaging system, Lilly has signed an agreement with Amersham for rights to Aequorea Victoria green fluorescent protein (GFP). Furthermore, Lilly has secured rights to operate under BioImage's Redistribution(TM) patent portfolio for monitoring intracellular signalling pathways, including protein translocation. Utilizing the advanced imaging quality and speed of the IN Cell Analyzer 3000 system in conjunction with the Aequorea Victoria GFP and Redistribution helps speed cellular screening capability and, ultimately, aid the discovery of new pharmaceuticals by examining disease-related targets in an informative biological context. "We are delighted to be working with Lilly in this area," said Mike Evans, Vice President of Marketing and Strategy, Discovery Systems at Amersham Biosciences, "Lilly's decision to utilize GFP and Redistribution technology together with the IN Cell Analyzer 3000 reflects the trend in the pharmaceutical industry towards generating biological information earlier in the drug development process to speed up the time to market. We look forward to working closely with Lilly in the future." "I am pleased that Lilly has chosen Redistribution to enhance its drug discovery program." said Dr. Patrik Dahlén, CEO of BioImage. "We are proud to have contributed with the Redistribution technology and look forward to its further utilization in drug discovery."

Other news from the department science

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures
View topic world

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures